Medigen Biotechnology Corp. (TPEX: 3176)

Market Cap	4.97B
Revenue (ttm)	1.39B
Net Income (ttm)	-433.07M
Shares Out	139.23M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,004
Open	35.70
Previous Close	35.70
Day's Range	35.70 - 35.80
52-Week Range	32.85 - 62.40
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cytotherapy, advanced nucleic acid testing, generic drugs, aesthetic medicine, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 3176

Financial Performance

In 2023, Medigen Biotechnology's revenue was 1.16 billion, an increase of 9.64% compared to the previous year's 1.06 billion. Losses were -561.30 million, -16.95% less than in 2022.